US4010A
(en)
*
|
|
1845-04-22 |
|
Island |
US3023A
(en)
*
|
|
1843-03-30 |
|
peters |
US3652589A
(en)
*
|
1967-07-27 |
1972-03-28 |
Gruenenthal Chemie |
1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
|
GB1584462A
(en)
|
1977-03-31 |
1981-02-11 |
Lafon Labor |
N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
|
FR2508035A1
(fr)
*
|
1981-06-23 |
1982-12-24 |
Fabre Sa Pierre |
Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
|
US4740198A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Method of administering intravenous drug using rate-controlled dosage form
|
US4882167A
(en)
|
1983-05-31 |
1989-11-21 |
Jang Choong Gook |
Dry direct compression compositions for controlled release dosage forms
|
US4571333A
(en)
*
|
1983-06-14 |
1986-02-18 |
Syntex (U.S.A.) Inc. |
Controlled release naproxen and naproxen sodium tablets
|
US4761501A
(en)
*
|
1983-10-26 |
1988-08-02 |
American Home Products Corporation |
Substituted phenylacetamides
|
US4795327A
(en)
*
|
1984-03-26 |
1989-01-03 |
Forest Laboratories, Inc. |
Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
|
US4849229A
(en)
*
|
1984-03-26 |
1989-07-18 |
Forest Laboratories, Inc. |
Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
|
US4781919A
(en)
|
1984-06-18 |
1988-11-01 |
Schering Corporation |
Sustained release dosage form
|
SE8404467D0
(sv)
*
|
1984-09-06 |
1984-09-06 |
Ferrosan Ab |
Controlled-release medical preparations
|
DE3572485D1
(en)
|
1984-12-22 |
1989-09-28 |
Thomae Gmbh Dr K |
Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
|
ATE66143T1
(de)
*
|
1985-01-11 |
1991-08-15 |
Abbott Lab |
Feste zubereitung mit langsamer freisetzung.
|
CA1270765A
(en)
*
|
1985-02-19 |
1990-06-26 |
Charles Hsiao |
Controlled release potassium chloride
|
GB8521494D0
(en)
|
1985-08-29 |
1985-10-02 |
Zyma Sa |
Controlled release tablet
|
US4734285A
(en)
*
|
1985-10-28 |
1988-03-29 |
The Dow Chemical Company |
Sustained release compositions
|
US4892742A
(en)
*
|
1985-11-18 |
1990-01-09 |
Hoffmann-La Roche Inc. |
Controlled release compositions with zero order release
|
IT1188212B
(it)
*
|
1985-12-20 |
1988-01-07 |
Paolo Colombo |
Sistema per il rilascio a velocita' controllata di sostanze attive
|
US4837032A
(en)
*
|
1986-02-04 |
1989-06-06 |
Farval Ag |
Theophylline sustained release tablet
|
IL78017A
(en)
*
|
1986-03-03 |
1989-06-30 |
Yissum Res Dev Co |
Sustained release tablets of theophylline
|
US4775535A
(en)
|
1986-04-04 |
1988-10-04 |
Hans Lowey |
Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
|
US4756911A
(en)
*
|
1986-04-16 |
1988-07-12 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
US4795642A
(en)
*
|
1986-05-01 |
1989-01-03 |
Pharmacaps, Inc. |
Gelatin-encapsulated controlled-release composition
|
US4708834A
(en)
|
1986-05-01 |
1987-11-24 |
Pharmacaps, Inc. |
Preparation of gelatin-encapsulated controlled release composition
|
US4798725A
(en)
*
|
1986-06-16 |
1989-01-17 |
Norwich Eaton Pharmaceuticals, Inc. |
Sustained release capsule
|
US4832957A
(en)
*
|
1987-12-11 |
1989-05-23 |
Merck & Co., Inc. |
Controlled release combination of carbidopa/levodopa
|
US4710384A
(en)
|
1986-07-28 |
1987-12-01 |
Avner Rotman |
Sustained release tablets made from microcapsules
|
US4816262A
(en)
*
|
1986-08-28 |
1989-03-28 |
Universite De Montreal |
Controlled release tablet
|
US4803076A
(en)
*
|
1986-09-04 |
1989-02-07 |
Pfizer Inc. |
Controlled release device for an active substance
|
US4861590A
(en)
*
|
1986-09-25 |
1989-08-29 |
Colgate-Palmolive Company |
Sustained release fluoride and calcium composition
|
US4800083A
(en)
*
|
1986-10-20 |
1989-01-24 |
R. P. Scherer Corporation |
Sustained release method and product
|
US4956388A
(en)
*
|
1986-12-22 |
1990-09-11 |
Eli Lilly And Company |
3-aryloxy-3-substituted propanamines
|
US4822619A
(en)
*
|
1987-02-18 |
1989-04-18 |
Ionor, Inc. |
Controlled release pharmaceutical preparation containing a gastrointestinal irritant drug
|
US4786503A
(en)
|
1987-04-06 |
1988-11-22 |
Alza Corporation |
Dosage form comprising parallel lamine
|
US4806359A
(en)
*
|
1987-04-22 |
1989-02-21 |
Mcneilab, Inc. |
Iburprofen sustained release matrix and process
|
US4792448A
(en)
|
1987-06-11 |
1988-12-20 |
Pfizer Inc. |
Generic zero order controlled drug delivery system
|
US4820522A
(en)
|
1987-07-27 |
1989-04-11 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
CA1323798C
(en)
*
|
1987-10-06 |
1993-11-02 |
Robert James Belanger |
Flakes of baking shortening or lard
|
FR2640972B1
(de)
*
|
1988-12-28 |
1991-04-19 |
Pf Medicament |
|
IT1237904B
(it)
*
|
1989-12-14 |
1993-06-18 |
Ubaldo Conte |
Compresse a rilascio a velocita' controllata delle sostanze attive
|
CA2041774C
(en)
|
1990-11-27 |
1994-04-19 |
Mircea A. Mateescu |
Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
|
US5603956A
(en)
*
|
1990-11-27 |
1997-02-18 |
Labopharm Inc. |
Cross-linked enzymatically controlled drug release
|
US5326570A
(en)
*
|
1991-07-23 |
1994-07-05 |
Pharmavene, Inc. |
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
|
US20020006963A1
(en)
*
|
1992-06-23 |
2002-01-17 |
Young James W. |
Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
|
GB9215043D0
(en)
|
1992-07-15 |
1992-08-26 |
Flow Inc K |
Fluid mass flow meters
|
US5260069A
(en)
|
1992-11-27 |
1993-11-09 |
Anda Sr Pharmaceuticals Inc. |
Pulsatile particles drug delivery system
|
US5773025A
(en)
*
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5397574A
(en)
*
|
1993-10-04 |
1995-03-14 |
Andrx Pharmaceuticals, Inc. |
Controlled release potassium dosage form
|
TW344661B
(en)
*
|
1993-11-24 |
1998-11-11 |
Lilly Co Eli |
Pharmaceutical composition for treatment of incontinence
|
US5935060A
(en)
*
|
1996-07-12 |
1999-08-10 |
First Opinion Corporation |
Computerized medical diagnostic and treatment advice system including list based processing
|
US5459164A
(en)
*
|
1994-02-03 |
1995-10-17 |
Boots Pharmaceuticals, Inc. |
Medical treatment
|
US5419917A
(en)
*
|
1994-02-14 |
1995-05-30 |
Andrx Pharmaceuticals, Inc. |
Controlled release hydrogel formulation
|
WO1995022521A1
(fr)
*
|
1994-02-22 |
1995-08-24 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Derive d'aminoalkylcyclopropane
|
US5458887A
(en)
|
1994-03-02 |
1995-10-17 |
Andrx Pharmaceuticals, Inc. |
Controlled release tablet formulation
|
US5458888A
(en)
|
1994-03-02 |
1995-10-17 |
Andrx Pharmaceuticals, Inc. |
Controlled release tablet formulation
|
US5399359A
(en)
*
|
1994-03-04 |
1995-03-21 |
Edward Mendell Co., Inc. |
Controlled release oxybutynin formulations
|
WO1995025504A1
(en)
*
|
1994-03-18 |
1995-09-28 |
Pharmavene, Inc. |
Emulsified drug delivery systems
|
US5399362A
(en)
*
|
1994-04-25 |
1995-03-21 |
Edward Mendell Co., Inc. |
Once-a-day metoprolol oral dosage form
|
US5464633A
(en)
|
1994-05-24 |
1995-11-07 |
Jagotec Ag |
Pharmaceutical tablets releasing the active substance after a definite period of time
|
CA2134038C
(en)
*
|
1994-06-16 |
1997-06-03 |
David Taiwai Wong |
Potentiation of drug response
|
US5792796A
(en)
*
|
1994-07-27 |
1998-08-11 |
Warner-Lambert Company |
Methods for treating anxiety and panic
|
US5658955A
(en)
*
|
1994-11-01 |
1997-08-19 |
Hitzig; Pietr |
Combined use of dopamine and serotonin agonists in the treatment of immune disorders
|
US6103263A
(en)
*
|
1994-11-17 |
2000-08-15 |
Andrx Pharmaceuticals, Inc. |
Delayed pulse release hydrogel matrix tablet
|
US5585115A
(en)
*
|
1995-01-09 |
1996-12-17 |
Edward H. Mendell Co., Inc. |
Pharmaceutical excipient having improved compressability
|
US5567441A
(en)
|
1995-03-24 |
1996-10-22 |
Andrx Pharmaceuticals Inc. |
Diltiazem controlled release formulation
|
US5824638A
(en)
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
DE69607904T2
(de)
|
1995-08-16 |
2000-10-05 |
Eli Lilly And Co., Indianapolis |
Potenzierung von Serotonin-Wirkstoffresponz
|
JP2000507945A
(ja)
*
|
1996-03-25 |
2000-06-27 |
イーライ・リリー・アンド・カンパニー |
痛みを処置する方法
|
WO1997035584A1
(en)
*
|
1996-03-25 |
1997-10-02 |
Eli Lilly And Company |
Method for treating pain
|
US5912256A
(en)
|
1996-06-20 |
1999-06-15 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
EP0818198A1
(de)
|
1996-07-09 |
1998-01-14 |
Lilly S.A. |
Potenzierung von Wirkstoffresponz durch erhöhte Verfügung von Serotonin
|
FR2752732B1
(fr)
|
1996-08-28 |
1998-11-20 |
Pf Medicament |
Forme galenique a liberation prolongee de milnacipran
|
GB9617990D0
(en)
*
|
1996-08-29 |
1996-10-09 |
Scotia Holdings Plc |
Treatment of pain
|
US6110498A
(en)
*
|
1996-10-25 |
2000-08-29 |
Shire Laboratories, Inc. |
Osmotic drug delivery system
|
US5837379A
(en)
|
1997-01-31 |
1998-11-17 |
Andrx Pharmaceuticals, Inc. |
Once daily pharmaceutical tablet having a unitary core
|
US5776969A
(en)
*
|
1997-02-27 |
1998-07-07 |
Eli Lilly And Company |
Treatment of sleep disorders
|
ES2203963T3
(es)
|
1997-05-30 |
2004-04-16 |
Osmotica Corp. |
Dispositivo osmotico multicapa.
|
US5885616A
(en)
*
|
1997-08-18 |
1999-03-23 |
Impax Pharmaceuticals, Inc. |
Sustained release drug delivery system suitable for oral administration
|
UA57107C2
(uk)
*
|
1997-09-23 |
2003-06-16 |
Елі Ліллі Енд Компані |
Спосіб лікування розладу поведінки
|
UA56257C2
(uk)
*
|
1997-09-23 |
2003-05-15 |
Елі Ліллі Енд Компані |
Спосіб лікування неадекватної визивної поведінки
|
AU9692898A
(en)
*
|
1997-10-17 |
1999-05-10 |
Eli Lilly And Company |
Potentiation of pharmaceuticals
|
US6096340A
(en)
*
|
1997-11-14 |
2000-08-01 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
US5916595A
(en)
*
|
1997-12-12 |
1999-06-29 |
Andrx Pharmaceutials, Inc. |
HMG co-reductase inhibitor
|
US6500853B1
(en)
|
1998-02-28 |
2002-12-31 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
US6099859A
(en)
*
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
US6106862A
(en)
*
|
1998-08-13 |
2000-08-22 |
Andrx Corporation |
Once daily analgesic tablet
|
US5994363A
(en)
|
1998-08-24 |
1999-11-30 |
Pentech Pharmaceuticals, Inc. |
Amelioration of apomorphine adverse effects
|
US6099862A
(en)
*
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6489341B1
(en)
|
1999-06-02 |
2002-12-03 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
|
US6573373B1
(en)
|
1999-06-29 |
2003-06-03 |
Isis Pharmaceuticals, Inc. |
High affinity, low molecular weight displacers for oligonucleotide purification
|
ATE305307T1
(de)
*
|
1999-07-01 |
2005-10-15 |
Pharmacia & Upjohn Co Llc |
Reboxetin zur behandlung von migränekopfschmerzen
|
BR0013017A
(pt)
*
|
1999-08-13 |
2002-04-16 |
Vela Pharmaceuticals Inc |
Usos de composições para o tratamento ou prevenção dos distúrbios do sono usando doses muito baixas de ciclobenzaprina
|
BR0013366A
(pt)
*
|
1999-08-16 |
2002-07-23 |
Revaax Pharmaceuticals Llc |
Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
|
US6432989B1
(en)
*
|
1999-08-27 |
2002-08-13 |
Pfizer Inc |
Use of CRF antagonists to treat circadian rhythm disorders
|
GB2355191A
(en)
*
|
1999-10-12 |
2001-04-18 |
Laxdale Ltd |
Combination formulations for fatigue, head injury and strokes
|
US6380200B1
(en)
*
|
1999-12-07 |
2002-04-30 |
Pfizer, Inc. |
Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
|
CN1396829A
(zh)
*
|
2000-02-24 |
2003-02-12 |
法玛西雅厄普约翰美国公司 |
新的药物联合形式
|
US20010036943A1
(en)
|
2000-04-07 |
2001-11-01 |
Coe Jotham W. |
Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
|
GB2362826A
(en)
|
2000-06-02 |
2001-12-05 |
Lilly Co Eli |
A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
|
CA2364211A1
(en)
*
|
2000-12-05 |
2002-06-05 |
Phillip Branch Chappell |
Combination treatment for depression, anxiety and psychosis
|
AU2002232470B2
(en)
|
2001-01-02 |
2005-11-03 |
Pharmacia & Upjohn Company Llc |
New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
|
US20020147196A1
(en)
|
2001-04-05 |
2002-10-10 |
Quessy Steven Noel |
Composition and method for treating neuropathic pain
|
PL366406A1
(en)
|
2001-04-19 |
2005-01-24 |
Warner-Lambert Company Llc |
Fused bicyclic or tricyclic amino acids
|
US6638981B2
(en)
*
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
RU2187307C1
(ru)
|
2001-10-15 |
2002-08-20 |
Сыров Кирилл Константинович |
Твердые стабильные лекарственные формы преднизолона
|
US20030082225A1
(en)
*
|
2001-10-19 |
2003-05-01 |
Mason Paul Arthur |
Sterile, breathable patch for treating wound pain
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
US6602911B2
(en)
*
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
US20040034101A1
(en)
*
|
2001-11-05 |
2004-02-19 |
Cypress Bioscience, Inc. |
Treatment and prevention of depression secondary to pain (DSP)
|
WO2003047560A1
(en)
*
|
2001-11-30 |
2003-06-12 |
Eli Lilly And Company |
Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
|
US20030143548A1
(en)
*
|
2002-01-28 |
2003-07-31 |
Camilleri Michael L. |
Predicting patient responsiveness to serotonergic therapy
|
EP1482921A1
(de)
*
|
2002-02-12 |
2004-12-08 |
Cypress Bioscience, Inc. |
Verfahren zur behandlung von aufmerksamkeitsdefizit/hyperaktivitätsstörungen (adhd)
|
CA2479350A1
(en)
|
2002-03-15 |
2003-09-25 |
Cypress Bioscience, Inc. |
Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
|
EP1499309A4
(de)
|
2002-04-24 |
2008-05-28 |
Cypress Bioscience Inc |
Prävention und behandlung von funktionellen somatischen erkrankungen, einschliesslich stressbedingten erkrankungen
|
EP1558231A4
(de)
*
|
2002-10-03 |
2010-09-08 |
Cypress Bioscience Inc |
Dosiseskalation und geteilte tagesdosis von antidepressiva zurbehandlung von neurologischen erkrankungen
|
US20060024366A1
(en)
*
|
2002-10-25 |
2006-02-02 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
US20040121010A1
(en)
*
|
2002-10-25 |
2004-06-24 |
Collegium Pharmaceutical, Inc. |
Pulsatile release compositions of milnacipran
|
JP2006515008A
(ja)
|
2003-01-28 |
2006-05-18 |
コレギウム ファーマシューティカル, インコーポレイテッド |
経口投与のためのミルナシプランの多粒子状組成物
|
FR2851163B1
(fr)
*
|
2003-02-14 |
2007-04-27 |
|
Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
|
WO2004105690A2
(en)
*
|
2003-05-23 |
2004-12-09 |
Cypress Bioscience, Inc. |
Treatment of chronic pain associated with drug or radiation therapy
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
US7787453B2
(en)
*
|
2006-08-03 |
2010-08-31 |
Broadcom Corporation |
Network interface controller with receive side scaling and quality of service
|
US20080058317A1
(en)
*
|
2006-08-09 |
2008-03-06 |
Cypress Bioscience, Inc. |
Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
|
US20080058318A1
(en)
|
2006-08-09 |
2008-03-06 |
Cypress Bioscience, Inc. |
Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
|
TW200911225A
(en)
|
2007-05-22 |
2009-03-16 |
Cypress Bioscience Inc |
Methods for improving physical function in fibromyalgia
|